abstract |
The invention relates to the use of a PAR-1 antagonist, in particular chosen from vorapaxar, atopaxar and 3-2- (chlorophenyl) -1- [4- (4-fluoro-benzyl) -piperazin-1-yl] -propenone, for the prevention and / or treatment of chronic inflammatory bowel and colon disease in a mammal, in particular Crohn's disease. |